Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
Alternative names
ad-reic/dkk-3 (2 trials)
mtg201 (1 trial)
nivolumab (opdivo) (1 trial)
Mesothelioma (Phase 2)
Prostatic Neoplasms (Phase 2)
Trials (3 total)
Trial APIs (3 total)